BioAtla (BCAB) Cash from Investing Activities (2020 - 2023)
BioAtla's (BCAB) quarterly Cash from Investing Activities came in at -$8000.0 in Q4 2023, up 74.19% year-on-year from -$4592.6 in Q4 2022, and up 68.0% quarter-over-quarter from -$25000.0 in Q3 2023.
BioAtla (BCAB) Cash from Investing Activities (2020 - 2023) Analysis & Trends
BioAtla's Cash from Investing Activities history runs 4 years deep, the most recent figure standing at -$8000.0 for Q4 2023.
- On a quarterly basis, Cash from Investing Activities rose 74.19% year-over-year to -$8000.0 in Q4 2023; TTM through Sep 2024 was -$8000.0, a 93.39% increase from a year earlier, with the FY2023 full-year figure at -$98000.0, up 63.02% from the prior year.
- Cash from Investing Activities improved to -$8000.0 in Q4 2023 per BCAB's latest filing, from -$25000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$8000.0 in Q4 2023 and bottomed at -$501000.0 in Q1 2021.
- The 4-year median for Cash from Investing Activities is -$62000.0 (2020), against an average of -$117312.5.
- Across the five-year window, Cash from Investing Activities plunged 2405.0% in 2021 and jumped 98.0% in 2022, its largest moves.
- Year by year, Cash from Investing Activities stood at -$395000.0 in 2020, then jumped by 77.47% to -$89000.0 in 2021, then surged by 65.17% to -$31000.0 in 2022, then surged by 74.19% to -$8000.0 in 2023.
- Per Business Quant, the three latest BCAB Cash from Investing Activities figures stand at -$8000.0 (Q4 2023), -$25000.0 (Q3 2023), and -$15000.0 (Q2 2023).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | -25.54 Mn |
| 10 | BioAtla | 5.12 Mn | 5.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -8,000.00 |
| Dec 31, 2023 | -8,000.00 |
| Sep 30, 2023 | -25,000.00 |
| Sep 30, 2023 | -25,000.00 |
| Jun 30, 2023 | -15,000.00 |
| Jun 30, 2023 | -15,000.00 |
| Mar 31, 2023 | -50,000.00 |
| Mar 31, 2023 | -50,000.00 |
| Dec 31, 2022 | -31,000.00 |
| Dec 31, 2022 | -31,000.00 |
| Sep 30, 2022 | -58,000.00 |
| Sep 30, 2022 | -58,000.00 |
| Jun 30, 2022 | -166,000.00 |
| Jun 30, 2022 | -166,000.00 |
| Mar 31, 2022 | -10,000.00 |
| Mar 31, 2022 | -10,000.00 |
| Dec 31, 2021 | -89,000.00 |
| Dec 31, 2021 | -89,000.00 |
| Sep 30, 2021 | -99,000.00 |
| Sep 30, 2021 | -99,000.00 |